- 83,000$100.3B
1
- 101,703$51.8B
2
- 16,458$7.7B
3
- 14,522$10.9B
4
- 50,000$58.1B
5
- 83,100$41.5B
6
Takeda
Manufacturing · Japan · 47,347 Employees
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, JapanRead More
View Company Info for Free
Who is Takeda
Headquarters
Phone Number
Website
Revenue
Stock Symbol
Industry
Top Competitors of Takeda
Compare CEO
How does Christophe Weber compare against Competing Companies' CEOs?
President, Chief Executive Officer & Represen...
CEO effectiveness to drive business results
VS.

Brenton Saunders
CEO at Allergan
CEO effectiveness to drive business results
Takeda Org Chart
Takeda Email Formats
Takeda uses at least 5 email formats with first.last (ex. John.Smith@takeda.com) being used 79.2% of the time
Takeda Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@takeda.com | 79.2% |
first.last | John.Smith@shire.com | 5.8% |
first.last | John.Smith@baxalta.com | 2.8% |
first initials + last | JSmith@shire.com | 1% |
first + last | JohnSmith@takeda.com |
Get Verified Emails
Takeda Company Metrics
Aug 27, 2020
Movetis NV
May 05, 2020
Adaptate Biotherapeutics
Apr 05, 2018
GammaDelta Therapeutics
Nov 01, 2017
Nycomed Pharma
Aug 20, 2016
BIKAM Pharmaceuticals
Sep 11, 2015
Coretherapix
See More Acquisitions & Subsidiaries
Takeda Tech Stack
Takeda News & Media
Biopharma Layoffs Continue Into 3Q23 - Contract Pharma
Pfizer's enterprise-wide cost realignment program to impact 100 jobs in Kildare and 500 jobs in Kent.The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with...Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficieHunter Syndrome Market to Register Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Denali Therapeutics Inc., JCR Pharmaceuticals Co., Ltd., REGENXBIO Inc., Shire, Takeda
The dynamics of the Hunter syndrome market are anticipated to change in the coming years owing to the launch of emerging therapies and improvement in research and development activities. The dynamics of the Hunter syndrome market are anticipated to change in the coming years owing to the launch of emerging therapies and improvement in research and development activities.
Frequently Asked Questions regarding Takeda
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such... Read More